Gynecologic Cancer

This article reviews the trials that have been conducted with PARP inhibitors in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and places the impact of those results in the larger context of PARP inhibitor development.
• The Maze of PARP Inhibitors in Ovarian Cancer
• The Circuitous Path of PARP Inhibitor Development in Epithelial Ovarian Cancer

CME
Patient education and counseling are essential in women at increased risk for ovarian and endometrial cancer. Women must be educated regarding the signs, symptoms, and risks associated with these cancers.
•The Complexity of Hereditary Cancer Syndromes

The timing and clinical benefit of a second debulking operation for recurrent disease is contentious. This article focuses on the recent debate regarding when—or whether—patients with ovarian cancer should undergo aggressive surgical resection.
• Controversies in the Management of Advanced Ovarian Cancer
• Is Neoadjuvant Chemotherapy an Excuse for Insufficient Surgery?

Epithelial ovarian cancer spreads prominently within the peritoneal cavity. In fact, we now know that high-grade serous cancers are often of tubal origin, and their presentation as tubo-ovarian masses renders it likely that IP spread occurs as an early event in their clinical evolution.
• Use of IP Chemotherapy in Ovarian Cancer: The Critical Questions
• Intraperitoneal Chemotherapy: Many Questions, Much Promise . . .

This article reviews recent advances in our understanding of ovarian cancer and its treatment in both the newly diagnosed and recurrent settings, and covers the use of intraperitoneal chemotherapy and the impact of biological therapies.
• Ovarian Cancer Care: It’s Time for “Personalized” Approaches
• Challenges to the Paclitaxel/Carboplatin Algorithm

A 46-year-old woman presented for medical evaluation due to a 2-month history of increasing difficulty in ambulation, especially getting up out of a chair or climbing stairs. She had also noticed swelling and discoloration of both upper eyelids (as depicted).

A 48-year-old African American female presents with severe uterine bleeding. She states that she has been bleeding very heavily for the past two days and the flow is increasing. She is also diabetic and hypertensive. Pelvic examination revealed an enlarged irregularly shaped uterus. A large mass was noted by ultrasonography and the uterus was removed. A section of the mass is evaluated.

A 58-year-old woman with recurrent/metastatic ovarian cancer involving bones, inguinal lymph nodes, and soft tissue of the back develops tender swelling and mild to moderate erythema of both legs two days after her first infusion of gemcitabine (Gemzar).